Context: You are scientist in a pharmaceutical company. Your superior has asked you to synthesize a new drug.
User: The compound should have a acute oral toxicity rat LD50 of 6251.0 mg/kg, 0 violations of the Ghose filter, 0 lead likeness filter violations, 4 Lipinski rule violations, 2285.676 molecular weight g/mol, 132 carbon atoms, and 0 oxygen atoms.
Assistant: Of course The chemical with the SMILES representation of CCCCN(c1nc(NCCCN(CCN(CCCNc2nc(N(CCCC)C3CC(C)(C)N(C)C(C)(C)C3)nc(N(CCCC)C3CC(C)(C)N(C)C(C)(C)C3)n2)c2nc(N(CCCC)C3CC(C)(C)N(C)C(C)(C)C3)nc(N(CCCC)C3CC(C)(C)N(C)C(C)(C)C3)n2)c2nc(N(CCCC)C3CC(C)(C)N(C)C(C)(C)C3)nc(N(CCCC)C3CC(C)(C)N(C)C(C)(C)C3)n2)nc(N(CCCC)C2CC(C)(C)N(C)C(C)(C)C2)n1)C1CC(C)(C)N(C)C(C)(C)C1 shows the desired properties.

Context: You are {#an assistant|researcher|scientist!} in a pharmaceutical company. Your {#boss|superior|department head!} has asked you to {#design|create|synthesize!} a new drug.
User: The {#drug|compound|chemical!} should have a {CATMoS_LD50_mgkg__names__noun} of {CATMoS_LD50_mgkg#} {CATMoS_LD50_mgkg__units}, {num_ghose_violations#} {num_ghose_violations__names__noun}, {num_lead_likeness_violations#} {num_lead_likeness_violations__names__noun}, {num_lipinski_violations#} {num_lipinski_violations__names__noun}, {molecular_mass#} {molecular_mass__names__noun} {molecular_mass__units}, {num_carbon_atoms#} {num_carbon_atoms__names__noun}, and {num_oxygen_atoms#} {num_oxygen_atoms__names__noun}.
Assistant: {#Happy to help!|Sure!|Of course!} The {#molecule|chemical|compound!} with the {SMILES__description} {#representation of |!}{SMILES#} {#shows|exhibits|displays!} the desired properties.

6-N-[3-[[4,6-bis[butyl-(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-1,3,5-triazin-2-yl]-[2-[[4,6-bis[butyl-(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-1,3,5-triazin-2-yl]-[3-[[4,6-bis[butyl-(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-1,3,5-triazin-2-yl]amino]propyl]amino]ethyl]amino]propyl]-2-N,4-N-dibutyl-2-N,4-N-bis(1,2,2,6,6-pentamethylpiperidin-4-yl)-1,3,5-triazine-2,4,6-triamine